

(Use additional sheets if necessary)



ATTY. DOCKET NO.
ON/4-32344A
APPLICATION NO.
10/505,399
APPLICANT
AVRAMIS ET AL.
FILING DATE
AUGUST 19, 2004

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AM						<input type="checkbox"/>	<input type="checkbox"/>
AN						<input type="checkbox"/>	<input type="checkbox"/>
AO						<input type="checkbox"/>	<input type="checkbox"/>
AP						<input type="checkbox"/>	<input type="checkbox"/>
AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Ottaviani et al., "Simultaneous in vitro exposure to Gleevec (formerly ST1571), Apo2L/TRAIL and Interferon alpha, with or without prior Ara-C treatment, Apo2L/TRAIL induced cytotoxicity and apoptosis in BCR/ABL + leukaemic blasts," <i>Blood</i> , Vol. 98(11), Part 2, pp. 265b-266b (2001)
/A.F./ AS	Marley et al., "Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia," <i>British Journal of Haematology</i> 2002, Vol. 116(1), pp. 162-165 (2002)
AT	"Chronic Myelogenous Leukemia and Investigational Treatment Strategies," <i>Leukemia Insights</i> , Online!, Vol. 6(3), pp. 1-9 (2001)

EXAMINER /Abigail Fisher/ DATE CONSIDERED 01/24/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

(Use several sheets if necessary)

ATTY. DOCKET NO.
CN/4-32344A
APPLICATION NO.
10/505,399
APPLICANT
AVRAMIS ET AL.
FILING DATE
AUGUST 19, 2004

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA Teply et al., "Synergistic activity of ST1571 with chemotherapeutic drugs and irradiation," *Blood*, Vol. 96(14), Part 1, p. 736a (2000)

DB Druker Brian J et al., "A phase I study of Gleevec (imatinib mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia-positive chronic myeloid leukemia (CML)," *Blood*, Vol. 98(11), Part 1, pp. 845A-846A (2001)

DC Ruchatz et al., "Co-administration of ST1571 and idarubicin increases the sensitivity to cytotoxic treatment in vitro and in vivo," *Blood*, Vol. 98(11), Part 1, pp. 101a-102a (2001)

DD Keating, "Leukemia: a model for drug development," *Clinical Cancer Research*, The American Association for Cancer Research, US, Vol. 3(12), Part 2, pp. 2608-2604 (1997)

DE Berman et al., "Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia," *Blood*, Vol. 77(6), p. 1060-1074 (1991)

DF Rose-La et al., "Insights from pre-clinical studies for new combination treatment regimens with the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective," *Leukemia*, Vol. 16(7), pp. 1213-1219 (2002)

DG

DH

DI

DJ

DK

DL

DM

DN

EXAMINER

/Abigail Fisher/

DATE CONSIDERED

01/24/2008

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.